News Releases

March 27, 2019
DURHAM, NC – March 27, 2019 – Bioventus , a global leader in orthobiologic solutions, is launching OSTEO AMP SELECT Fibers , an innovative addition to its allograft line of OSTEOAMP bone graft substitutes for spine, foot & ankle, orthopaedic, and trauma surgeons.
January 29, 2019
HOOFDDORP, THE NETHERLANDS – January 29, 2019 – Bioventus , a global leader in orthobiologic solutions, is launching DUROLANE , its single-injection joint-fluid osteoarthritis (OA) treatment, in Malaysia and has selected Athrotech as its exclusive distribution partner for the market.
January 15, 2019
DURHAM, NC – January 15, 2019 – Bioventus , a global leader in orthobiologic solutions, is launching OSTEOMATRIX+, its next generation biphasic bone graft for use in bone remodeling in a variety of orthopaedic and spine applications. OSTEOMATRIX+ is a moldable bone graft substitute consisting of
October 25, 2018
DURHAM, NC – October 25, 2018 – Bioventus , a global leader in orthobiologic solutions, today announced the appointment of Susan M. Stalnecker, former Vice President and Treasurer, E.I. du Pont de Nemours and Company, to the company’s Board of Managers, replacing Michael Minogue.
July 23, 2018
DURHAM, NC – July 23, 2018 – Bioventus , a global leader in orthobiologic solutions, has entered into a definitive agreement to divest its next generation bone morphogenetic protein (BMP) development program to a new company formed by Viscogliosi Brothers, LLC (VB) , a private equity investment
March 5, 2018
DURHAM, NC – March 5, 2018 – Bioventus , a global leader in orthobiologic solutions, today launched DUROLANE , its single-injection, hyaluronic acid (HA) product used for joint lubrication in the treatment of pain associated with knee osteoarthritis (OA) .
Displaying 31 - 40 of 44